Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine
Abstract.: Several lines of evidence suggest that cholinergic deficits may contribute to the pathophysiology of psychiatric disorders as well as Alzheimer’s disease. There is growing clinical evidence that galantamine, currently used for the treatment of Alzheimer’s disease, may improve cognitive dy...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2011-01-01
|
| Series: | Journal of Pharmacological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319307145 |
| _version_ | 1819099001092308992 |
|---|---|
| author | Yukio Ago Ken Koda Kazuhiro Takuma Toshio Matsuda |
| author_facet | Yukio Ago Ken Koda Kazuhiro Takuma Toshio Matsuda |
| author_sort | Yukio Ago |
| collection | DOAJ |
| description | Abstract.: Several lines of evidence suggest that cholinergic deficits may contribute to the pathophysiology of psychiatric disorders as well as Alzheimer’s disease. There is growing clinical evidence that galantamine, currently used for the treatment of Alzheimer’s disease, may improve cognitive dysfunction and psychiatric illness in schizophrenia, major depression, bipolar disorder, and alcohol abuse. Since galantamine is a rather weak acetylcholinesterase inhibitor, but has additional allosteric potentiating effects at nicotinic receptors, it affects not only cholinergic transmission but also other neurotransmitter systems such as monoamines, glutamate, and γ-aminobutyric acid (GABA) through its allosteric mechanism. It is likely that these effects may result in more beneficial effects. To understand the underlying mechanism for the clinical effectiveness of galantamine, neuropharmacological studies have been performed in animal models of several psychiatric disorders. These studies suggest that not only the nicotinic receptor–modulating properties but also the muscarinic receptor activation contribute to the antipsychotic effect and improvement of cognitive dysfunction by galantamine. This review summaries the current status on the pharmacology of galantamine, focusing on its effect on neurotransmitter release and pharmacological studies in animal models of psychiatric disorders. Keywords:: galantamine, psychiatric disorder, acetylcholinesterase, nicotinic and muscarinic receptors, neurotransmitter release |
| first_indexed | 2024-12-22T00:39:56Z |
| format | Article |
| id | doaj.art-baa744ecce904d4b9ec62f9aee5953c0 |
| institution | Directory Open Access Journal |
| issn | 1347-8613 |
| language | English |
| last_indexed | 2024-12-22T00:39:56Z |
| publishDate | 2011-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmacological Sciences |
| spelling | doaj.art-baa744ecce904d4b9ec62f9aee5953c02022-12-21T18:44:42ZengElsevierJournal of Pharmacological Sciences1347-86132011-01-011161617Pharmacological Aspects of the Acetylcholinesterase Inhibitor GalantamineYukio Ago0Ken Koda1Kazuhiro Takuma2Toshio Matsuda3Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, JapanLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, JapanLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, JapanLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan; Department of Experimental Disease Model, The Osaka-Hamamatsu Joint Research Center for Child Mental Development, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; Corresponding author (affiliation #1). matsuda@phs.osaka-u.ac.jpAbstract.: Several lines of evidence suggest that cholinergic deficits may contribute to the pathophysiology of psychiatric disorders as well as Alzheimer’s disease. There is growing clinical evidence that galantamine, currently used for the treatment of Alzheimer’s disease, may improve cognitive dysfunction and psychiatric illness in schizophrenia, major depression, bipolar disorder, and alcohol abuse. Since galantamine is a rather weak acetylcholinesterase inhibitor, but has additional allosteric potentiating effects at nicotinic receptors, it affects not only cholinergic transmission but also other neurotransmitter systems such as monoamines, glutamate, and γ-aminobutyric acid (GABA) through its allosteric mechanism. It is likely that these effects may result in more beneficial effects. To understand the underlying mechanism for the clinical effectiveness of galantamine, neuropharmacological studies have been performed in animal models of several psychiatric disorders. These studies suggest that not only the nicotinic receptor–modulating properties but also the muscarinic receptor activation contribute to the antipsychotic effect and improvement of cognitive dysfunction by galantamine. This review summaries the current status on the pharmacology of galantamine, focusing on its effect on neurotransmitter release and pharmacological studies in animal models of psychiatric disorders. Keywords:: galantamine, psychiatric disorder, acetylcholinesterase, nicotinic and muscarinic receptors, neurotransmitter releasehttp://www.sciencedirect.com/science/article/pii/S1347861319307145 |
| spellingShingle | Yukio Ago Ken Koda Kazuhiro Takuma Toshio Matsuda Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine Journal of Pharmacological Sciences |
| title | Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine |
| title_full | Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine |
| title_fullStr | Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine |
| title_full_unstemmed | Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine |
| title_short | Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine |
| title_sort | pharmacological aspects of the acetylcholinesterase inhibitor galantamine |
| url | http://www.sciencedirect.com/science/article/pii/S1347861319307145 |
| work_keys_str_mv | AT yukioago pharmacologicalaspectsoftheacetylcholinesteraseinhibitorgalantamine AT kenkoda pharmacologicalaspectsoftheacetylcholinesteraseinhibitorgalantamine AT kazuhirotakuma pharmacologicalaspectsoftheacetylcholinesteraseinhibitorgalantamine AT toshiomatsuda pharmacologicalaspectsoftheacetylcholinesteraseinhibitorgalantamine |